Allan Reine, MD
Allan Reine is an experienced biotechnology chief financial officer and investor who has been active in the industry since 2001.
He has been Chief Financial Officer (CFO) of Foghorn Therapeutics since 2019. Previously, Allan was CFO of Pieris Pharmaceuticals, Inc. Prior to that, he was an investor for almost 15 years, managing various healthcare portfolios focused on biotechnology and pharmaceutical companies at Lombard Odier Asset Management, Citi Principal Strategies, SAC Capital Advisors, Trivium Capital and Alexandra Investment Management. He started his career at CIBC World Markets where he worked in both biotechnology investment banking and biotechnology equity research.
Allan received his MD from the University of Toronto, and his Bachelor of Science in statistical sciences from the University of Western Ontario.
In addition to his role as independent Non-Executive Director he also serves as Chair of our Audit Committee.